Waystar Closes Acquisition of Iodine Software, Extending AI Leadership in Healthcare Software
Waystar (NASDAQ:WAY) has successfully completed its acquisition of Iodine Software, a strategic move that combines one of the industry's largest financial datasets with one of the largest clinical datasets. The acquisition expands Waystar's total addressable market by over 15% by adding Iodine's client base of more than 1,000 hospitals and health systems.
The deal is expected to be immediately accretive to gross margin and adjusted EBITDA margin, with positive impacts on revenue growth and non-GAAP net income per diluted share anticipated by 2027. The combination strengthens Waystar's AI-powered platform by integrating comprehensive clinical and financial intelligence, enhancing automation in healthcare revenue cycle management.
Waystar (NASDAQ:WAY) ha portato a termine l'acquisizione di Iodine Software, una mossa strategica che unisce uno dei più grandi dataset finanziari del settore a uno dei maggiori dataset clinici. L'acquisizione amplia il mercato indirizzabile totale di Waystar di oltre il 15%, aggiungendo una base clienti di oltre 1.000 ospedali e sistemi sanitari.
L'accordo dovrebbe apportare immediatamente miglioramenti al margine lordo e al margine EBITDA rettificato, con effetti positivi attesi sulla crescita dei ricavi e sull'utile per azione diluita non GAAP entro il 2027. L'integrazione rafforza la piattaforma alimentata dall'IA di Waystar integrando intelligence clinica e finanziaria, potenziando l'automazione nel ciclo di reddito del settore sanitario.
Waystar (NASDAQ:WAY) ha completado con éxito la adquisición de Iodine Software, una jugada estratégica que fusiona uno de los mayores conjuntos de datos financieros de la industria con uno de los mayores conjuntos de datos clínicos. La compra amplía el mercado total direccionable de Waystar en más del 15%, al incorporar la base de clientes de Iodine compuesta por más de 1.000 hospitales y sistemas de salud.
Se espera que el acuerdo aporte márgenes brutos y EBITDA ajustado de forma inmediata, con impactos positivos en el crecimiento de ingresos y en el beneficio neto no GAAP por acción diluida previsto para 2027. La combinación fortalece la plataforma impulsada por IA de Waystar al integrar inteligencia clínica y financiera, mejorando la automatización en la gestión del ciclo de ingresos en la atención médica.
Waystar (NASDAQ:WAY)가 Iodine Software의 인수를 성공적으로 completed해 업계의 가장 큰 재무 데이터 세트 중 하나와 가장 큰 임상 데이터 세트를 결합하는 전략적 움직임을 성사시켰습니다. 이 인수로 Waystar의 총 주소 가능 시장이 15% 이상 확장되며, Iodine의 1,000곳이 넘는 병원과 건강 시스템의 고객 기반이 추가됩니다.
해당 거래는 즉시 총마진 및 조정 EBITDA 마진에 긍정적인 효과를 낼 것으로 기대되며, 2027년까지 매출 성장 및 비-GAAP 희석 주당 순이익에 긍정적 영향을 미칠 것으로 예측됩니다. 이 조합은 컴프리헨시클 임상 및 재무 정보를 통합해 Waystar의 AI 기반 플랫폼을 강화하고, 헬스케어 수익 순환 관리의 자동화를 향상시킵니다.
Waystar (NASDAQ:WAY) a mené à bien l’acquisition de Iodine Software, une démarche stratégique qui réunit l’un des plus grands ensembles de données financières du secteur et l’un des plus grands ensembles de données cliniques. L’acquisition élargit le marché adressable total de Waystar de plus de 15%, en ajoutant une base de clients de plus de 1 000 hôpitaux et systèmes de santé.
L’accord devrait être immédiatement bénéficiaire sur la marge brute et la marge EBITDA ajustée, avec des effets positifs attendus sur la croissance du chiffre d’affaires et le bénéfice net non-GAAP par action diluée d’ici 2027. Cette combinaison renforce la plateforme alimentée par l’IA de Waystar en intégrant des informations cliniques et financières complètes, améliorant l’automatisation du cycle de revenu dans la gestion des revenus de soins de santé.
Waystar (NASDAQ:WAY) hat erfolgreich die Übernahme von Iodine Software abgeschlossen, eine strategische Maßnahme, die einen der größten finanziellen Datensätze der Branche mit einem der größten klinischen Datensätze verbindet. Die Übernahme erweitert den insgesamt adressierbaren Markt von Waystar um über 15%, indem Iodines Kundenstamm von mehr als 1.000 Krankenhäusern und Gesundheitssystemen hinzugefügt wird.
Der Deal wird voraussichtlich sofort zu einer Verbesserung der Bruttomarge und der bereinigten EBITDA-Marge führen, mit positiven Auswirkungen auf das Umsatzwachstum und den non-GAAP Gewinn pro verwässerter Aktie, die bis 2027 erwartet werden. Die Kombination stärkt die von KI getriebene Plattform von Waystar, indem sie umfassende klinische und finanzielle Intelligence integriert und die Automatisierung im Revenue-Cycle-Management im Gesundheitswesen verbessert.
Waystar (NASDAQ:WAY) أكملت بنجاح استحواذها على Iodine Software، وهي خطوة استراتيجية تجمع بين أحد أكبر مجموعات البيانات المالية في الصناعة مع أحد أكبر مجموعات البيانات السريرية. توسع الصفقة السوق القابل للوصول الكلي لـ Waystar بأكثر من 15% من خلال إضافة قاعدة عملاء تحتوي على أكثر من 1,000 مستشفى ونظام صحي.
من المتوقع أن تكون الصفقة مربحة من الفور للمحصلة الإجمالية وهوامش EBITDA المعدلة، مع تأثيرات إيجابية على نمو الإيرادات وهوامش صافي الدخل غير GAAP للسهم المخفف بحلول 2027. ستعزز الدمج منصة Waystar المعتمدة على الذكاء الاصطناعي عبر دمج معلومات سريرية ومالية شاملة، ما يحسن التشغيل الآلي في إدارة دورة الإيرادات الرعاية الصحية.
Waystar (NASDAQ:WAY) 已成功完成对 Iodine Software 的收购，这是一次战略性举动，将业内最大的财务数据集之一与最大的临床数据集之一结合起来。此次收购通过增加 Iodine 的客户基础（超过 1,000 家医院和卫生系统），将 Waystar 的总可服务市场扩大了 超过 15%。
交易预计将立即提升毛利率和经调整的 EBITDA 利润率，对收入增长和非 GAAP 稀释后每股收益的积极影响预计将于 2027 实现。此次整合通过结合全面的临床与财务情报，强化了 Waystar 的 AI 驱动平台，提升在医疗保健收入循环管理中的自动化水平。
- Immediate accretion to gross margin and adjusted EBITDA margin
- 15% expansion in total addressable market with addition of 1,000+ hospitals and health systems
- Enhanced cross-selling opportunities through combined client base
- Integration of comprehensive clinical and financial datasets strengthening AI capabilities
- Expected accretion to revenue growth and non-GAAP EPS by 2027
- Integration execution risks with large-scale acquisition
- Delayed accretion to revenue growth and EPS until 2027
Insights
Waystar's acquisition of Iodine Software expands market reach by 15%, enhances AI capabilities, and strengthens financial profile with immediate margin benefits.
Waystar (WAY) has completed its strategic acquisition of Iodine Software, creating a powerful combination that merges extensive financial and clinical datasets to enhance its AI-powered healthcare payment platform. This transaction has three significant dimensions worth analyzing.
First, the market expansion is substantial. By incorporating Iodine's client base of over 1,000 hospitals and health systems, Waystar immediately expands its total addressable market by more than 15%. This creates meaningful cross-selling opportunities across their combined customer base, driving potential revenue synergies.
Second, the financial impact appears favorable. The acquisition is expected to be immediately accretive to both gross margin and adjusted EBITDA margin – indicating the deal should enhance profitability from day one. The company also projects it will boost revenue growth and non-GAAP earnings per share by 2027. This suggests a thoughtful integration timeline with realistic expectations for fully realizing synergies.
Third, and perhaps most strategically valuable, is the technology integration. By combining what they describe as "one of the industry's largest financial datasets with one of the largest clinical datasets," Waystar is positioning itself at the critical intersection between clinical care delivery and financial claims processing. This expanded visibility across the healthcare payment ecosystem should strengthen their AI capabilities and help providers capture previously lost revenue.
The acquisition aligns with healthcare's increasing focus on AI-driven efficiency, particularly in revenue cycle management where proper clinical documentation and coding directly impact reimbursement. By bridging clinical and financial data, Waystar can potentially deliver more comprehensive solutions that reduce administrative burden while maximizing provider compensation.
Unites industry-leading AI-powered financial and clinical intelligence on Waystar's cloud-based software platform
Expands total addressable market by more than
Iodine's client base of more than 1,000 hospitals and health systems expands Waystar's total addressable market by over
Uniting Iodine's expertise in the critical stage between care delivery and claim submission provides Waystar expansive visibility across the healthcare payment ecosystem—fueling next-generation AI capabilities that prevent revenue leakage and ensure providers are paid fully and accurately.
"Iodine joining Waystar brings together comprehensive clinical and financial intelligence on a single AI-powered platform — a unique differentiator in the market," said Matt Hawkins, Chief Executive Officer of Waystar. "This further powers automation in the revenue cycle, strengthens financial performance, and leverages combined data assets to drive a continuously learning AI platform that maximizes client outcomes."
Barclays served as exclusive financial advisor, and Simpson Thacher & Bartlett LLP served as legal advisor to Waystar. J.P. Morgan Securities served as exclusive financial advisor, and Weil, Gotshal & Manges LLP and Queen Saenz + Schultz PLLC served as legal advisors to Iodine.
About Waystar
Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 16 of 20 institutions on the
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that reflect our current views with respect to, among other things, statements regarding Waystar's expectations relating to future operating results and financial position, the impact of the Iodine acquisition and our ability to successfully integrate it and realize the anticipated benefits; the performance of our new product offerings; our industry and market opportunities, business strategy, goals, and expectations concerning our market position, future operations, margins and profitability, and other financial and operating information. Forward-looking statements include all statements that are not historical facts. These statements may include words such as "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "seek," "foreseeable," "outlook," the negative version of these words or similar terms and phrases to identify forward-looking statements in this press release, including the discussion of Waystar's expanded addressable market and the accretive impact of the Iodine acquisition.
The forward-looking statements contained in this press release are based on management's current expectations and are not guarantees of future performance. The forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith, and we believe there is a reasonable basis for them. However, there can be no assurance that management's expectations, beliefs, and projections will result or be achieved. The following factors are among those that may cause actual results to differ materially from the forward-looking statements: our operation in a highly competitive industry; our ability to retain our existing clients and attract new clients; our ability to successfully execute on our business strategies in order to grow; our ability to accurately assess the risks related to acquisitions and successfully integrate acquired businesses (including the acquisition of Iodine); our ability to establish and maintain strategic relationships; the growth and success of our clients and overall healthcare transaction volumes; consolidation in the healthcare industry; our selling cycle of variable length to secure new client agreements; our implementation cycle that is dependent on our clients' timing and resources; our dependence on our senior management team and certain key employees, and our ability to attract and retain highly skilled employees; the accuracy of the estimates and assumptions we use to determine the size of our total addressable market; our ability to develop and market new solutions, or enhance our existing solutions, to respond to technological changes, or evolving industry standards; the interoperability, connectivity, and integration of our solutions with our clients' and their vendors' networks and infrastructures; the performance and reliability of internet, mobile, and other infrastructure; the consequences if we cannot obtain, process, use, disclose, or distribute the highly regulated data we require to provide our solutions; our reliance on certain third-party vendors and providers; any errors or malfunctions in our products and solutions; failure by our clients to obtain proper permissions or provide us with accurate and appropriate information; the potential for embezzlement, identity theft, or other similar illegal behavior by our employees or vendors, and a failure of our employees or vendors to observe quality standards or adhere to environmental, social, and governance standards; our compliance with the applicable rules of the National Automated Clearing House Association and the applicable requirements of card networks; increases in card network fees and other changes to fee arrangements; the effect of payer and provider conduct which we cannot control; privacy concerns and security breaches or incidents relating to our platform; the complex and evolving laws and regulations regarding privacy, data protection, and cybersecurity; our ability to adequately protect and enforce our intellectual property rights; our ability to use or license data and integrate third-party technologies; our use of "open source" software; legal proceedings initiated by third parties alleging that we are infringing or otherwise violating their intellectual property rights; claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties; the heavily regulated industry in which we conduct business; the uncertain and evolving healthcare regulatory and political framework; healthcare laws and data privacy and security laws and regulations governing our processing of personal information; reduced revenues in response to changes to the healthcare regulatory landscape; legal, regulatory, and other proceedings that could result in adverse outcomes; consumer protection laws and regulations; contractual obligations requiring compliance with certain provisions of the Bank Secrecy Act and anti-money laundering laws and regulations; existing laws that regulate our ability to engage in certain marketing activities; our full compliance with website accessibility standards; any changes in our tax rates, the adoption of new tax legislation, or exposure to additional tax liabilities; limitations on our ability to use our net operating losses to offset future taxable income; losses due to asset impairment charges; restrictive covenants in the agreements governing our credit facilities; interest rate fluctuations; unavailability of additional capital on acceptable terms or at all; the impact of general macroeconomic conditions; actions of certain of our significant investors, who may have different interests than the interests of other holders of our securities; our status as an "emerging growth company" and whether the reduced disclosure requirements applicable to "emerging growth companies" will make our common stock less attractive to investors; and each of the other factors discussed under the heading of "Risk Factors" in the Company's 10K filed with the Securities and Exchange Commission (the "SEC") on February 18, 2025, and in other reports filed with the SEC, all of which are available on the Investor Relations page of our website at investors.waystar.com.
Any forward-looking statements made by us in this press release speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. You should not place undue reliance on our forward-looking statements. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by any applicable securities laws.
Media Contact
Kristin Lee
kristin.lee@waystar.com
Daniel Yunger / Nick Capuano / Mark Fallati
Kekst CNC
kekst-waystar@kekstcnc.com
Investor Contact
investors@waystar.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/waystar-closes-acquisition-of-iodine-software-extending-ai-leadership-in-healthcare-software-302571823.html
SOURCE Waystar
FAQ
What is the strategic rationale behind Waystar's acquisition of Iodine Software?
How will the Iodine Software acquisition impact Waystar's (WAY) market reach?
When will the Iodine acquisition become accretive to Waystar's (WAY) earnings?
What are the expected synergies from Waystar's acquisition of Iodine Software?
Who were the advisors in the Waystar-Iodine acquisition deal?
